Key points are not available for this paper at this time.
Design
Review
Does not support routine adoption; leaves open prospective validation before guideline integration in heart failure.
SrdeÄnĂ selhĂĄnĂ pĹedstavuje vĂ˝znamnĂ˝ medicĂnskĂ˝ problĂŠm, jehoĹž incidence a prevalence stoupĂĄ. U pacientĹŻ s diagnĂłzou srdeÄnĂho selhĂĄnĂ, a to akutnĂho a chronickĂŠho, je vÄdecky ovÄĹen vĂ˝znam stanovovĂĄnĂ koncentracĂ natriuretickĂ˝ch peptidĹŻ, a to natriuretickĂŠho peptidu typu B (BNP) a N-terminĂĄlnĂho fragmentu natriuretickĂŠho propeptidu typu B (NT-proBNP). V klinickĂŠ praxi hodnota natriuretickĂ˝ch peptidĹŻ pomĂĄhĂĄ jednak v stanovenĂ diagnĂłzy srdeÄnĂho selhĂĄnĂ, jednak v urÄenĂ prognĂłzy srdeÄnĂho selhĂĄnĂ. PĹi podrobnĂŠm studiu patofyziologie srdeÄnĂho selhĂĄnĂ se objevilo nÄkolik novĂ˝ch potenciĂĄlnĂch biomarkerĹŻ srdeÄnĂho selhĂĄnĂ. Jde o solubilnĂ ST2, galektin, kopeptin a mid-regionĂĄlnĂ fragment pro-adrenomedulinu (MR-proADM). Tyto novĂŠ biomarkery by mohly usnadĹovat diagnostiku a stanovenĂ prognĂłzy akutnĂho i chronickĂŠho srdeÄnĂho selhĂĄnĂ.
No takes yet. Share an insight, caveat, or question.
Vondráková et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: